NasdaqGS:HALO - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	1,701	975	N/A	N/A	4
12/31/2026	1,481	811	864	870	7
12/31/2025	1,245	597	615	622	8
3/31/2025	1,084	485	496	504	N/A
12/31/2024	1,015	444	468	479	N/A
9/30/2024	947	392	393	403	N/A
6/30/2024	873	337	408	420	N/A
3/31/2024	863	319	424	431	N/A
12/31/2023	829	282	373	389	N/A
9/30/2023	781	254	354	369	N/A
6/30/2023	774	234	293	306	N/A
3/31/2023	705	182	264	279	N/A
12/31/2022	660	202	235	240	N/A
9/30/2022	581	211	238	240	N/A
6/30/2022	487	366	290	292	N/A
3/31/2022	472	435	287	289	N/A
12/31/2021	443	403	298	299	N/A
9/30/2021	463	409	265	268	N/A
6/30/2021	412	229	150	152	N/A
3/31/2021	331	163	116	119	N/A
12/31/2020	268	129	53	55	N/A
9/30/2020	200	22	-24	-22	N/A
6/30/2020	180	-40	-60	-58	N/A
3/31/2020	164	-80	-89	-86	N/A
12/31/2019	196	-72	-89	-85	N/A
9/30/2019	203	-40	-55	-48	N/A
6/30/2019	182	-43	-43	-38	N/A
3/31/2019	178	-51	-36	-32	N/A
12/31/2018	152	-80	N/A	-49	N/A
9/30/2018	281	46	N/A	93	N/A
6/30/2018	319	76	N/A	132	N/A
3/31/2018	318	68	N/A	134	N/A
12/31/2017	317	63	N/A	134	N/A
9/30/2017	166	-88	N/A	-35	N/A
6/30/2017	134	-120	N/A	-64	N/A
3/31/2017	134	-116	N/A	-60	N/A
12/31/2016	147	-103	N/A	-50	N/A
9/30/2016	160	-71	N/A	-50	N/A
6/30/2016	149	-67	N/A	-58	N/A
3/31/2016	159	-37	N/A	-36	N/A
12/31/2015	135	-32	N/A	-37	N/A
9/30/2015	113	-42	N/A	-23	N/A
6/30/2015	107	-38	N/A	-19	N/A
3/31/2015	82	-57	N/A	-44	N/A
12/31/2014	75	-68	N/A	-48	N/A
9/30/2014	57	-85	N/A	-62	N/A
6/30/2014	59	-84	N/A	-61	N/A

애널리스트 미래 성장 예측

수입 대 저축률: HALO 의 연간 예상 수익 증가율( 14.8% )이 saving rate( 2.9% 보다 높습니다. ).

수익 vs 시장: HALO 의 연간 수익( 14.8% ) US 시장( 14.3% 보다 빠르게 성장할 것으로 예상됩니다. 14.3% 연간).

고성장 수익: HALO 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: HALO 의 수익(연간 12.4% ) US 시장( 8.6% 보다 빠르게 성장할 것으로 예상됩니다. 8.6% 연간).

고성장 수익: HALO 의 수익(연간 12.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: HALO 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 58.5 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/23 22:40
장 마감 주가	2025/05/23 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Halozyme Therapeutics, Inc. 34 애널리스트 중 8 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Ishan Majumdar	Baptista Research
James Birchenough	Barclays
Robert Wasserman	Benchmark Company

Halozyme Therapeutics 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for 2025

Halozyme Therapeutics, Inc. Raises Earnings Guidance for the Full Year 2025

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2024

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for 2024

Recent updates

Investor sentiment deteriorates as stock falls 15%

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. to Report Q1, 2025 Results on May 06, 2025

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Halozyme Therapeutics, Inc. Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?

Halozyme Therapeutics, Inc. Announces the Retirement of Michael J. LaBarre as Senior Vice President, Chief Technical Officer

Halozyme Therapeutics, Inc., Annual General Meeting, May 01, 2025

Halozyme Therapeutics: Steady Growth In A Challenged Market

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

President exercised options and sold US$3.9m worth of stock

Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for 2025

Connie L. Matsui Announces Not to Stand for Re-Election to the Board of Halozyme Therapeutics, Inc

Halozyme Therapeutics, Inc. to Report Q4, 2024 Results on Feb 18, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Might Not Be As Mispriced As It Looks

Halozyme Therapeutics, Inc. Raises Earnings Guidance for the Full Year 2025

Halozyme: Recent Approvals Alter My Appetite

Halozyme Therapeutics, Inc argenx's VYDURA with ENHANZE® is Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Therapeutics (NASDAQ:HALO) Seems To Use Debt Rather Sparingly

Investor sentiment deteriorates as stock falls 15%

Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Investor sentiment improves as stock rises 18%

Halozyme: Looking For More Growth Following Record Q3 Earnings

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2024

Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet

Halozyme Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Halozyme Therapeutics: Behind The Pullback

President notifies of intention to sell stock

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

President notifies of intention to sell stock

Extended Patent Protections And New Approvals Propel Revenue And Earnings Growth

Independent Director recently sold US$1.7m worth of stock

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for 2024

Senior VP & CTO notifies of intention to sell stock

Halozyme Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Senior VP & CFO notifies of intention to sell stock

Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Therapeutics, Inc. Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Independent Director recently sold US$1.0m worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 11% to US$57.11

Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024

Halozyme Therapeutics: The Story Brightens

Investor sentiment improves as stock rises 19%

Senior VP & CTO exercised options and sold US$743k worth of stock

Price target increased by 8.3% to US$51.44

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Halozyme Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Senior VP & Chief Technical Officer exercised options and sold US$606k worth of stock

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Senior VP & Chief Technical Officer exercised options and sold US$612k worth of stock

Senior VP & Chief Technical Officer notifies of intention to sell stock

Full year 2023 earnings: EPS exceeds analyst expectations

President exercised options and sold US$735k worth of stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

President exercised options and sold US$601k worth of stock

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market